Abbott forecasts 2024 earnings largely below estimates, shares down
Reuters
Published Jan 24, 2024 07:34AM ET
Updated Jan 24, 2024 09:27AM ET
(Reuters) -Abbott Laboratories on Wednesday forecast 2024 profit largely below Wall Street estimates despite meeting quarterly earnings expectations, sending the medical device maker's shares down 2.5% in premarket trading.
Expectations around performance of medical device makers have increased over the last one month after health insurers flagged higher medical costs earlier this month as people, especially older adults, go back for medical procedures they had delayed during the pandemic.
Abbott's forecast also follows strong earnings beat by peers Johnson & Johnson (NYSE:JNJ) and Intuitive Surgical (NASDAQ:ISRG), with bellwether J&J also expecting medtech-related procedures to remain elevated in 2024.
At first glance, Abbott's profit forecast is "a touch light" compared to Wall Street expectations, Mizuho Securities analyst Anthony Petrone said.
He added that medical devices sales beat was driven by its electrophysiology products, which may face competition later this year from newer devices to treat irregular heart rhythm.
Overall, the medical devices unit generated $4.44 billion in sales for the fourth quarter, higher than estimates of $4.33 billion.
The strong med-tech sales was also partly due to strength of its glucose monitoring device FreeStyle Libre, which brought in sales of $1.4 billion in the fourth quarter, up 25.5% year-on-year.
Abbott is banking on Libre for growth, targeting annual sales of $10 billion by 2028.
Its diagnostic segment revenue, which surged during the pandemic, recorded sales of $2.5 billion, in line with estimates but down 22.7% due to a sharp fall in COVID-19 testing-related sales.
It recorded COVID testing sales of $288 million, but did not provide an annual outlook.
Abbott also forecast 2024 adjusted profit in the range of $4.50 to $4.70 per share, with the mid-point below analysts' estimate of $4.64 per share, according to LSEG data.
Excluding items, Abbott's quarterly profit was in line with the average of analysts' estimates of $1.19 per share.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.